Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ceralifimod

Kleemann joins Merck from Boehringer

Appointed head of group tax

Biogen Idec building

Biogen Idec wins EU battle on Tecfidera exclusivity

Oral MS drug gains New Active Substance status

- PMLiVE

Sales down at Merck Serono on Rebif pressure

New MS drugs impact pharma company’s revenues

Biogen Idec building

Rocketing Tecfidera sales give Biogen Idec stellar Q3 results

Oral MS drug on course for blockbuster status in first year

- PMLiVE

Merck Serono completes move to Germany

Closes Swiss headquarters to take up residence with parent company in Darmstadt

New CEO for Merck Serono

Belén Garijo replaces Stefan Oschmann, who moves into a wider group role

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Sanofi reception

Sanofi wins EU approval for second MS drug in a month

EC approves Lemtrada weeks after Aubagio gets greenlight

- PMLiVE

Merck KGaA appoints new chief information officer

Promotes the head of its strategy realisation office James Stewart

- PMLiVE

Currencies hit Merck Serono sales but firm says it is ‘on course’

Overall groups sales down to €2.84bn for second quarter of 2013

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

Biogen Idec building

Biogen Idec signs brain research deal with Edinburgh University

Will identify potential treatments for multiple sclerosis and motor neurone disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links